Characterization of Acute Lymphoblastic Leukemia Subtypes in Moroccan Children
Table 3
Immunophenotypic profiles of 275 de novo acute lymphoblastic leukaemia.*
Markers
T-cell ALL
pB-cell ALL
CD1a+
45/56 (80.4)
—
sCD3+
49/59 (83.1)
0/216 (0.0)
cCD3+
57/57 (100)
0/216 (0.0)
CD4+
42/51 (82.4)
—
CD5+
54/55 (98.2)
—
CD7+
59/59 (100)
7/216 (3.2)
CD8+
32/52 (61.5)
—
CD10+
10/47 (21.3)
197/216 (91.2)
cyCD79a+
0/48 (0.0)
162/162 (100)
CD19+
1/59 (1.7)
216/216 (100)
CD20+
0/8 (0.0)
26/48 (54.2)
CD22+
1/47 (2.1)
216/216 (100)
CyIg+
—
18/58 (31.0)
SIg+
—
2/58 (3.5)
TdT+
31/44 (70.5)
142/158 (89.8)
CD34+
25/59 (42.4)
160/216 (74.1)
HLA-DR+
4/39 (10.3)
152/155 (98.1)
CD13+
13/59 (22)
100/216 (46.3)
CD33+
9/49 (15.3)
75/216 (34.7)
CD13+,CD33+
2/59 (3.4)
51/216 (23.6)
CD13-,CD33+
7/59 (11.9)
24/216 (11.1)
CD13+,CD33-
11/59 (18.6)
49/216 (22.7)
CD13+ and/or CD33+
20/59 (33.9)
124/216 (57.4)
CD13-, CD33-
39/59 (66.1)
92/216 (42.6)
CD45+
59/59 (100)
187/216 (87)
ALL: acute lymphoblastique leukaemia, : not applicable, MPO: myeloperoxidase, TdT: terminal deoxynucleotidyl transferase, cy: cytoplasmique, s: surface, +: positive, : negative, Ig: immunoglobulin. Result are given as number positive/number tested (% positive).Mature B-cell ALL excluded.
